GPCRs are one of the most important families of therapeutic targets in the pharmaceutical industry. They are involved in several pathologies, ranging from neurological, oncological, degenerative, metabolic, immunological… around a third of the drugs in clinical use are GPCR ligands
High-content screening (HCS) has become a cornerstone in GPCR and phenotypic drug discovery, enabling researchers to quantify cellular responses with spatial, temporal, and mechanistic depth.
For GPCR-focused programs, the ability to visualize receptor localization, internalization kinetics, and ligand interactions in intact cells offers advantages that extend far beyond traditional biochemical or radioligand assays.
Yet, despite remarkable progress, HCS workflows rema